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ValidationAbstract A simple method for simultaneous determination of gatiﬂoxacin and prednisolone ace-
tate in ophthalmic formulation was developed and validated using UV spectrophotometry. Gati-
ﬂoxacin and prednisolone acetate were quantiﬁed using the ﬁrst-order derivative of the UV
spectra. The proposed method was validated according to the guidelines of the International Con-
ference on Harmonization and the Association of Ofﬁcial Analytical Chemists International. The
measurements were made in acetonitrile/water (70:30 v/v) at 348 nm for gatiﬂoxacin and at
263 nm for prednisolone acetate. The calibration curves were linear in the concentration range of
3–21 lg mL1 for gatiﬂoxacin and 6–42 lg mL1 for prednisolone acetate with Sandell’s sensitivi-
ties of 0.349 lg cm2 and 0.402 lg cm2, respectively. The mean recovery and the limit of quanti-
ﬁcation for gatiﬂoxacin were 99.76 ± 0.41% and 1.11 lg mL1 and for prednisolone acetate were
99.52 ± 0.87% and 0.55 lg mL1, respectively. The method was precise, with a relative standard
deviation of less than 2.50% for both drugs. For robustness, the factors analyzed did not signiﬁ-
cantly affect the quantiﬁcation of gatiﬂoxacin and prednisolone acetate. The results of the validated
method did not differ signiﬁcantly from high-performance liquid chromatography (HPLC), whichrst-order
2 R.A. Sversut et al.
Please cite this article in press as: Sversut, R.A
UV derivative spectroscopy. Arabian Journawas previously developed and validated for the same drugs. In this form, the method was suitable
for routine analysis of gatiﬂoxacin and prednisolone acetate in their combined dosage form in oph-
thalmic formulations.
ª 2014 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Gatiﬂoxacin (GFN) is chemically known as 1-cyclopropyl-6-
ﬂuoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-
oxo-3-quinolinecarboxylic acid (O’Neil, 2006). The empirical
formula of GFN is C19H22FN3O4 and the molecular weight
is 384.40 g mol1 (Fig. 1a). GFN is a fourth-generation ﬂuoro-
quinolone that has been widely used in the prophylaxis and
treatment of ocular infections (Long et al., 2003; Donnenfeld
et al., 2004; Bucci et al., 2008; Callegan et al., 2009;
Cervantes and Mah, 2011).
Prednisolone acetate (PRED) is chemically known as 1,4-
pregnadiene-11b,17a,21-triol-3,20-dione 21-acetate (O’Neil,
2006). It has an empirical formula of C23H30O6 and a molecu-
lar weight of 402.48 g mol1 (Fig. 1b). PRED is one of the
most effective drugs of the synthetic glucocorticoid group used
for treatment of ocular inﬂammatory diseases (Akram et al.,
2010; Ibrahim et al., 2010).
Various pharmaceutical combinations of ﬂuoroquinolones
and topical corticosteroids have been proposed in recent years
(Roland and Wall, 2008; Wall et al., 2009; Campos et al.,
2011). Clinical studies have demonstrated the safety and efﬁ-
cacy of these combinations in the treatment and prophylaxis
of ocular infections caused by Gram-positive (Staphylococcus
aureus, Staphylococcus epidermidis and Streptococcus pneumo-
niae) and Gram-negative (Haemophilus inﬂuenzae) bacteria
(Mohan et al., 2001; Belfort et al., 2012). In the Brazilian mar-
ket, Allergan Inc. launched the ﬁrst and still the only ﬁxed-
dose combination containing GFN (0.3%) and PRED
(1.0%) in ophthalmic suspension (Zypred). This formulation
was approved by ANVISA (National Agency of Sanitary Sur-
veillance) in April 2010 for the treatment and prophylaxis of
ocular infections (Anvisa, 2013).
Various analytical methods have been described for the
estimation of GFN or PRED in biological ﬂuids
(Vishwanathan et al., 2001; Al-Dgither et al., 2006; Zhang
et al., 2006; Srinivas et al., 2008; Li et al., 2012).Figure 1 Chemical structure o
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high-pressure liquid chromatography (HPLC) (Venugopal
et al., 2007; Abida et al., 2011), UV spectrophotometry
(Salgado and Oliveira, 2005; Venugopal and Saha, 2005;
Jane et al., 2006; Amin et al., 2007; Kanakapura and
Rangachar, 2007; Darwish et al., 2010) and capillary zone
electrophoresis (Sane et al., 2005) were reported. UV spectro-
photometric and HPLC methods have been used to estimate
PRED in pharmaceutical dosage forms (Singh and Verma,
2007; Ghosh et al., 2011). A few methods were also given for
the simultaneous determination of ﬂuoroquinolones and corti-
costeroids in combined dosage form (Sireesha and Prakash,
2011; Prakash and Sireesha, 2012; Barot et al., 2012; Patel
and Sejal, 2013; Razzaq et al., 2012).
No analytical method has yet been reported in the ofﬁcial
compendia for the simultaneous determination of GFN and
PRED in ophthalmic formulations. The present study
attempted to develop a rapid, economical, precise and accurate
method for simultaneous determination of GFN and PRED in
ophthalmic formulation. The ﬁrst-derivative spectrophotome-
try method permits simultaneous analysis of both compounds
without previous separation and extraction procedures. This
alternative is simpler and less expensive than HPLC methods
(Paschoal and Ferreira, 2000; Sversut et al., 2014).
The results for precision obtained by this spectrophotome-
try method were statistically compared to those obtained by
the HPLC method, which was previously developed and vali-
dated by our research group.
2. Experimental
2.1. Apparatus
A Thermo Scientiﬁc Evolution 60 UV–Visible Spectropho-
tometer was used for the UV measurements. All drugs and ref-
erence substances were weighed on a Shimadzu analytical
balance (AY 220, Shimadzu Corp., Japan).f (a) GFN and (b) PRED.
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Simultaneous determination of gatiﬂoxacin and prednisolone acetate 32.2. Materials and reagents
The GFN and PRED reference substances (assigned purity
100.0%)were kindly donated byAllergan, Inc., Sa˜o Paulo, Brazil
(batch numbers 2010090113 andF201011031, respectively), and
were used as reference standards without further puriﬁcation.
The samples of ophthalmic suspension containing 0.3% GFN
and 1% PRED (declared content) were also donated by
Allergan, Inc. The GFN and PRED reference substances, as
well as the commercial formulations, were kept protected
from light throughout all stages of the study. Analytical-grade
acetonitrile (Proquı´mios, Rio de Janeiro, Brazil) and freshly
distilled water were used in all solution preparations.
2.3. Method development
2.3.1. Selection of the solvent
Different mixtures of solvents were investigated. For selection
of the solvent, the criteria employed were the ease of preparing
the standards and samples, solubility and stability of the drugs,
cost of the solvent, and applicability of the method.
2.3.2. Selection of wavelengths
The working standard solutions of GFN and PRED were
diluted with acetonitrile/water (70:30 v/v) to obtain a solution
containing 5 lg mL1 GFN and 15 lg mL1 PRED. Approx-
imately 3.0 mL was removed and scanned from 200 to 400 nm
with the UV spectrophotometer. The ﬁrst-order derivative UV
spectra of GFN and PRED were calculated from the UV
absorption spectra, and the best wavelengths were determined.
The choice of an optimum wavelength for each drug was
based on the fact that the absolute value of the ﬁrst-order
derivative absorption spectrum provided the best linear
response for the analyte concentration, without interference
from other components of the mixture.
2.3.3. Preparation of standard solutions
The standard solutions were prepared by weighing 10 mg of
GFN and 15 mg of PRED in 200 mL and 100 mL volumetric
ﬂasks, respectively. Acetonitrile/water (70:30 v/v) was added to
each ﬂask to obtain the working standard solutions of
50 lg mL1 GFN and 150 lg mL1 PRED.
2.3.4. Preparation of sample solution
The sample solution was prepared in the same ratio as the
labeled amounts of GFN and PRED in an ophthalmic formu-
lation. An aliquot of 5 mL was transferred to a 100 mL volu-
metric ﬂask, and the volume was completed with acetonitrile/
water (70:30 v/v) to obtain a stock sample solution containing
150 lg mL1 GFN and 500 lg mL1 PRED.
From the above stock solutions, 5 mL was added to 95 mL
of acetonitrile/water (70:30 v/v) to give ﬁnal concentrations of
7.5 and 25.0 lg mL1 of GFN and PRED, respectively.
2.4. Method validation
Validation of the new simultaneous spectrophotometry
method was carried out as recommended by the International
Conference on Harmonization (ICH, 2005) and the
Association of Ofﬁcial Analytical Chemists InternationalPlease cite this article in press as: Sversut, R.A. et al., Simultaneous determination of g
UV derivative spectroscopy. Arabian Journal of Chemistry (2014), http://dx.doi.org(AOAC, 2005) for the parameters of linearity, limit of detec-
tion (LOD), limit of quantiﬁcation (LOQ), precision, accuracy,
speciﬁcity, and robustness.
2.4.1. Linearity
Seven aliquots of working standard solutions for each drug
were used to determine the calibration curves. These curves
were plotted in the concentration ranges of 3.0–21.0 lg mL1
for GFN and 6.0–42.0 lg mL1 for PRED. The values of the
ﬁrst-order derivative UV spectra at 348 nm for GFN and at
263 nm for PRED as a function of the drug concentration were
used to construct the calibration curves. All spectrophotomet-
ric determinations were performed in triplicate and at room
temperature (25 ± 2 C). The linear regression was calculated
by the method of least squares, and the curves were evaluated
by analysis of variance (ANOVA).
2.4.2. Limits of detection and quantitation
LOD and LOQ were calculated based on the standard devia-
tion of the response and the slope of the calibration curve.
They were obtained using the following equations,
respectively:
LOD ¼ 3:3  SDb=a ð1Þ
LOQ ¼ 10:0  SDb=a ð2Þ
where SDb represents the standard deviation of the y-intercept
and a is the slope of the calibration curve (AOAC, 2005).
2.4.3. Precision
The intra-day precision (repeatability) was evaluated by ana-
lyzing sample solutions at single concentrations of GFN and
PRED, to span the linear range of the method (7.5 and
25.0 lg mL1, respectively). The analyses were performed in
six replicates on the same day. To estimate the inter-day preci-
sion, the sample solutions were freshly prepared at the same
concentration level for each drug, and the responses were
determined in six replicates. This procedure was performed
on three consecutive days. The intra- and inter-day precisions
are expressed in terms of Relative Standard Deviation
(%RSD).
2.4.4. Accuracy
The accuracy was calculated based on the percentage of recov-
ery of the known amounts of GFN and PRED added to the
samples (AOAC, 2005; Paim et al., 2012). Aliquots of the
GFN and PRED standard solutions in concentrations of 80,
120 and 160 lg mL1 were transferred to 10 mL volumetric
ﬂasks containing 5 mL of sample solution. The volumes were
completed with acetonitrile/water (70:30 v/v) and the drugs
were determined in triplicate, using the proposed method.
2.4.5. Speciﬁcity
The speciﬁcity of the method was evaluated through analysis
of a placebo solution. The mixture of inert components includ-
ing benzalkonium chloride, dibasic sodium phosphate, mono-
basic sodium phosphate, ethylenediamine tetraacetic acid,
hypromellose, hydrochloric acid and sodium hydroxide was
prepared in the usual concentrations employed in ophthalmic
formulations. These solutions were analyzed by the proposedatiﬂoxacin and prednisolone acetate in ophthalmic formulation using ﬁrst-order
/10.1016/j.arabjc.2014.11.026
Figure 2 Zero-order UV spectra of GFN (dotted line), GFN
(dashed line) and placebo (solid line) in acetonitrile/water (70:30 v/v).
4 R.A. Sversut et al.method in order to determine if any of the components of the
formulation might affect the determinations of GFN and
PRED.
2.4.6. Robustness
Robustness testing was performed in order to evaluate the sus-
ceptibility of measurements to deliberate variations in analyti-
cal conditions (Paim et al., 2012). The robustness test was
designed according to Abdullah et al. (2014). Different vol-
umes of known concentrations of GFN and PRED were added
to pre-analyzed samples containing 3.75 and 12.50 lg mL1 of
GFN and PRED, respectively. Then, the recoveries of the
added standard were measured under different analytical con-
ditions. The analytical conditions selected to examine the
robustness were percentage of acetonitrile (±5.0%), tempera-
ture (room and refrigerator temperatures) and wavelength
(±2 nm). While one condition was changed, the others
remained unchanged (at normal level). The results were evalu-
ated by means of the t-test.
2.5. Application of the method
The ophthalmic suspensions were analyzed at concentrations
of 7.5 and 25.0 lg mL1 for GFN and PRED, respectively, fol-
lowing the methodology used to prepare the sample solution.
All determinations were performed in 5 replicates and at room
temperature. The amounts of GFN and PRED were deter-
mined by ﬁtting the responses of the derivatives into the equa-
tions for the calibration curves of GFN and PRED.
2.6. Comparison of methods
In order to compare the UV derivative spectrophotometry
method with the previously validated HPLC method, the
results for precision of these methods were compared by
one-way ANOVA.Figure 3 First-order derivative spectra (dA/dk) of GFN (dotted
line) and PRED (solid line) in acetonitrile/water (70:30 v/v).3. Results and discussion
3.1. Method development
Considering the solubility and the stability, the following sol-
vents were tested as diluents of GFN and PRED standard
and sample solutions: water, basic water, acidic water, metha-
nol, ethanol and acetonitrile. The ﬁrst solvent studied was
water. GFN was easily soluble in 100% water, and PRED
was insoluble.
A study using the HPLC method showed the instability of
GFN and PRED in acid and basic solutions (Sversut et al.,
2014). Therefore, these solutions were not used. The methanol
and ethanol solutions did not provide good zero crossing
points for either drug.
After these preliminary tests, the mixture of acetoni-
trile:water (70:30, v/v) was used as the diluent to develop the
method, and afforded satisfactory solubility and stability of
GFN and PRED. This solvent offers an additional advantage
because it shows lower absorption in the UV region, indicating
that it did not affect the analysis of GFN and PRED.
The zero-order UV spectrum was inappropriate for analyz-
ing this binary mixture because of the UV spectral overlap ofPlease cite this article in press as: Sversut, R.A. et al., Simultaneous determination of
UV derivative spectroscopy. Arabian Journal of Chemistry (2014), http://dx.doi.orgGFN and PRED, which did not permit the simultaneous anal-
ysis of both drugs (Fig. 2). However, the use of the ﬁrst-order
derivative UV absorption spectra allowed these drugs to be
determined simultaneously (Fig. 3). The derivative values were
taken at 348 nm for GFN (zero-crossing of PRED) and at
263 nm for PRED (zero-crossing of GFN).
3.2. Method validation
3.2.1. Linearity
The statistical results of the linear regression and calibration
curves for GFN and PRED are shown in Table 1. The corre-
lation coefﬁcients indicated good linearity: 0.9997 and 0.9996
for GFN and PRED, respectively. The linearity ranges were
3.0–21.0 lg mL1 for GFN and 6.0–42.0 lg mL1 for PRED.
The absorbance values for these concentration ranges
remained between 0.3 and 1.5, conforming to the recommen-
dations of Vogel (2002). The UV spectrophotometric method
for simultaneous determination of GFN or PRED in a com-
bined dosage form shows a smaller range of concentrations
(Patel and Sejal, 2013).gatiﬂoxacin and prednisolone acetate in ophthalmic formulation using ﬁrst-order
/10.1016/j.arabjc.2014.11.026
Table 1 Parameters for calibration curves of GFN and PRED using ﬁrst-order derivative absorption spectra (dA/dk).
Parameters GFN PRED
Linearity range (lg mL1) 3.0–21.0 6.0–42.0
Wavelength (nm) 348 263
Regression equation dA/dk= 0.0011C+ 0.0001 dA/dk= 0.001C  0.0001
Correlation coeﬃcient (r) 0.9997 0.9996
p-Valuea <<0.05 (p= 2.50 · 1023) <<0.05 (p= 2.70 · 1031)
a Theoretical value of p is based on the one-way ANOVA test at a= 0.05 level of signiﬁcance.
Table 2 Precision of intra-day and inter-day results for simultaneous determination of GFN and PRED by the ﬁrst-order derivative
UV spectrophotometric method.
Druga Intra-dayb Inter-dayc
Day 1 Day 2 Day 3
GFN (lg mL1) 7.55 ± 0.11 7.45 ± 0.05 7.30 ± 0.08 7.43 ± 0.17
Content found (%) 100.62 ± 1.34 99.28 ± 0.60 97.31 ± 1.07 99.07 ± 2.23
PRED (lg mL1) 24.93 ± 0.07 25.02 ± 0.07 25.19 ± 0.07 25.05 ± 0.13
Content found (%) 99.70 ± 0.28 100.09 ± 0.27 100.76 ± 0.28 100.18 ± 0.52
a Theoretical concentration: 7.50 lg mL1 for GFN and 25.0 lg mL1 for PRED.
b Mean of 6 determinations.
c Mean of determinations on 3 different days.
Simultaneous determination of gatiﬂoxacin and prednisolone acetate 53.2.2. Limits of detection and quantitation
The sensitivity was determined using Sandell’s sensitivity and
using Eqs. (1) and (2) to calculate the values for LOD and
LOQ, respectively. Sandell’s sensitivities were of 0.349 lg cm2
(GFN) and 0.402 lg cm2 (PRED). The LODs were 0.33 and
0.16 lg mL1 for GFN and PRED, and the LOQs were 1.11
and 0.55 lg mL1 for GFN and PRED, respectively. These
values show that the proposed method has good sensitivity.
The methods reported in the literature for determination of
GFN or PRED in ophthalmic formulations are less sensitive,
as demonstrated by Sireesha and Prakash (2011) and Barot
et al. (2012), who obtained LOQ values of 1.203 lg mL1
and 1.957 lg mL1 respectively, for GFN and PRED.
3.2.3. Precision
The precision parameters (%RSD) expressed as repeatability
(intra-day) and as intermediate precision (inter-day) are pre-
sented in Table 2. For GFN, the values of %RSD were
1.34%, 0.60%, and 1.07% for repeatability in analyses per-
formed during 3 consecutive days, and 2.23% for intermediate
precision. For PRED, all %RSD values were lower than 1%.Table 3 Recovery data for standard solutions added to the samples
Drug Fortiﬁed theoretical concentration (lg mL1) Experimental co
GFN 11.75 11.63
15.75 15.63
19.75 19.51
PRED 20.50 20.28
24.50 24.36
28.50 28.44
a Mean of 3 determinations.
Please cite this article in press as: Sversut, R.A. et al., Simultaneous determination of g
UV derivative spectroscopy. Arabian Journal of Chemistry (2014), http://dx.doi.orgThus, our proposed method has good precision in the simulta-
neous determination of GFN and PRED.’
3.2.4. Accuracy
The recovery percentages were 99.76 ± 0.41% and
99.52 ± 0.87% for GFN and PRED, respectively (Table 3).
These results indicate the accuracy of the method.
3.2.5. Speciﬁcity
The speciﬁcity test demonstrated that the excipients did not
affect the drug determination (Fig. 2). Our method showed
good speciﬁcity in the UV ﬁrst-order derivative for unequivo-
cal determination of the analyte in the presence of matrix com-
pounds (excipients).
3.2.6. Robustness
The responses of GFN and PRED did not change signiﬁcantly
when the analytical conditions were modiﬁed (Table 4). These
observations conﬁrm the robustness of the method for deter-
mination of GFN and PRED in ophthalmic formulation.analyzed by the ﬁrst-derivative UV spectrophotometric method.
ncentration founda (lg mL1) Recovery (%) Mean recovery (%)
99.96 99.76 ± 0.41
100.02
99.29
98.58 99.52 ± 0.87
99.69
100.29
atiﬂoxacin and prednisolone acetate in ophthalmic formulation using ﬁrst-order
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Table 5 Commercial ophthalmic formulation analysis.a
Drug Theoretical concentrationb (lg mL1) Measured concentrationc (%)
GFN 7.5 100.53 ± 0.62
PRED 25 99.94 ± 0.19
a The ophthalmic formulation was Zypred (Allergan Inc., Sa˜o Paulo, Brazil) containing labeled amounts of 3.0 mg mL1 GFN and
10 mg mL1 PRED.
b The theoretical concentration followed the same ratio as the labeled amounts of GFN and PRED in the ophthalmic formulation.
c Mean of 5 determinations.
Table 4 Robustness evaluation of the ﬁrst-derivative UV spectrophotometric method.
Recovery (%) at diﬀerent spectrophotometric conditions (mean ± SD)a
Drugb Normal conditionsc Percentage of
acetonitrile (+5.0%)
Percentage of
acetonitrile (5.0%)
Wavelength
(+2.0 nm)
Wavelength
(2.0 nm)
Refrigerator
temperature (8 C)
GFN 100.12 ± 1.17 98.83 ± 0.86 98.83 ± 0.86 98.13 ± 1.88 99.32 ± 0.98 97.38 ± 0.50
PRED 98.77 ± 0.64 100.93 ± 1.80 97.42 ± 1.43 97.90 ± 2.08 97.53 ± 0.25 96.87 ± 1.00
a Mean of 5 determinations.
b Added amount of each drug: 8 lg mL1.
c Normal spectrophotometric conditions: ﬁrst-derivative UV spectrophotometric method using the mixture acetonitrile: water (70:30, v/v) as
solvent at 263 nm (for PRED) and 348 nm (for GFN). All analyses were performed at room temperature (25 ± 2 C).
6 R.A. Sversut et al.3.3. Application of the method
The proposed UV spectrophotometric method is suitable for
simultaneous determination of GFN and PRED in their com-
bined ophthalmic dosage form in routine analysis. Table 5
shows the results for simultaneous determination of GFN
and PRED in an ophthalmic formulation, using this method.3.4. Method comparison
The UV derivative spectrophotometry and HPLC methods
were compared through one-way ANOVA, using the mean
values obtained for the precision of the methods. The tech-
niques did not differ signiﬁcantly (Fcalc < Fcrit and p< 0.05).
These results show the capacity of the derivative spectropho-
tometry method to simultaneously quantify GFN and PRED
in ophthalmic formulation with precision comparable to
HPLC, which is a more expensive and complicated technique.4. Conclusion
A UV spectrophotometric method was developed and vali-
dated for the simultaneous determination of GFN and PRED
in ophthalmic formulations. The method showed speciﬁcity,
precision, accuracy, sensitivity and robustness, as evaluated
according to ICH and AOAC guidelines. The proposed
method proved to be simpler, less expensive, and faster,
because no additional pretreatment of the samples is required
prior to the measuring step, thus accelerating the quality-con-
trol process. The lack of a signiﬁcant difference from the pre-
viously validated HPLC method conﬁrms that the UV
derivative spectrophotometry method is suitable, useful, and
an excellent alternative to assess quality in routine analysis
of GFN and PRED in drug products.Please cite this article in press as: Sversut, R.A. et al., Simultaneous determination of
UV derivative spectroscopy. Arabian Journal of Chemistry (2014), http://dx.doi.orgAcknowledgments
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